ReviewClinical reviews in allergy & immunology2019
The Unique Molecular Signatures of Contact Dermatitis and Implications for Treatment.
Review in Clinical reviews in allergy & immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 75 citations in OpenAlex.
- The OX40-OX40L Co-Stimulatory Pathway as a Shared Driver of Immune Persistence in Skin and Airway Inflammation.Clinical reviews in allergy & immunology · 2026Review
- T helper and IL-20 cytokine signatures distinguish atopic dermatitis from contact dermatitis subtypes.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Review
- Requirements for Alternative In Vitro and In Silico Skin Models of Irritant and Allergic Contact Dermatitis.Contact dermatitis · 2025Review
- A Practical Approach to Chronic Hand Eczema.Dermatology and therapy · 2025Article
- Th1 and Th2 cytokine expression in hyperkeratotic chronic hand eczema and the role of Tofacitinib a oral JAK inhibitor.Archives of dermatological research · 2024Article
- Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment Decisions.Immune network · 2024Review
- Beyond Avoidance: Advanced Therapies for Contact Dermatitis.The journal of allergy and clinical immunology. In practice · 2024Review
- Endothelial Protein C Receptor and 3K3A-Activated Protein C Protect Mice from Allergic Contact Dermatitis in a Contact Hypersensitivity Model.International journal of molecular sciences · 2024Article
- Regulatory framework for development and marketing authorization of allergen products for diagnosis of rare type I and type IV allergies: The current status.Allergologie select · 2024Review
- Allergic Contact Dermatitis in Pediatric Practice.Current pediatric reviews · 2024Review
- A short-term high-sugar diet is an aggravating factor in experimental allergic contact dermatitis.Heliyon · 2023Article
- Looking beyond Self-Protection: The Eyes Instruct Systemic Immune Tolerance Early in Life.Brain sciences · 2023Article
- Role of Innate Immunity in Allergic Contact Dermatitis: An Update.International journal of molecular sciences · 2023Review
- Molecular perspective of efficiency and safety problems of chemical enhancers: bottlenecks and recent advances.Drug delivery and translational research · 2022Review
- Thioredoxin-1: A Promising Target for the Treatment of Allergic Diseases.Frontiers in immunology · 2022Review
- Innate Immune Mechanisms in Contact Dermatitis.Handbook of experimental pharmacology · 2022Article
- Pruritus: A Sensory Symptom Generated in Cutaneous Immuno-Neuronal Crosstalk.Frontiers in pharmacology · 2022Review
- What We Have Learned-Milestones in Pediatric Contact Dermatitis.Current dermatology reports · 2022Review
- Occupational Chronic Contact Dermatitis Successfully Treated with Dupilumab: A Case Series.Dermatology (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritant contact dermatitis (ICD) and allergic contact dermatitis (ACD) are common skin disorders that are characterized by inflammation, oozing, crusting, and pruritus. Atopic dermatitis (AD) is an inflammatory skin disease characterized by immune and barrier abnormalities and is additionally a risk factor for acquiring ICD and ACD. New work on allergic sensitization to common allergens (e.g., nickel and fragrance) in human skin has shown that different allergens have distinct molecular fingerprinting. For example, nickel promotes strong Th1/Th17 polarization, whereas fragrance allergy causes Th2/Th22 skewing, which is similar to the phenotype of AD. While ACD has previously been considered to be constant across all allergens, largely based on mouse models involving strong sensitizers, these new data suggest that ACD differs mechanistically according to allergen. Further, ACD in the setting of concurrent AD shows a different and attenuated phenotype as compared to healthy individuals with ACD, which influences the way AD patients respond to vaccination and other treatment modalities. As in contact sensitization, skin challenged by food patch testing shows that common food allergens (e.g., peanut and barley) also cause distinct immune polarizations in the skin. Additionally, house dust mite reactions in human skin have been profiled to show unique Th2, Th9, and Th17/22 activation as compared to controls, which are similar to the phenotype of psoriasis and contact responses to nickel. Given this information, ACD patients should be treated based on their unique allergen polarity. Refined understanding of the molecular behavior of contact dermatitis and related diseases translates to improved methods of inducing tolerance in sensitized allergic patients, such as with targeted drug therapy and epicutaneous immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.